Skip to content
Tirzepatide Report
Provider review

Lyfe Rx Tirzepatide Review: Price, Refund Fees and FDA History

Researched & written by Alan PierceClinical Pharmacology WriterUpdated

FDA warning letter
FDA issued Lyfe Rx a warning letter in September 2025 (Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)). Read the letter on FDA’s own warning-letter database.

On this page

Lyfe Rx identifies compounded tirzepatide with an embedded catalog amount; selected supply and payment terms require confirmation.

Standout details

  • Names compounded tirzepatide in current product information
  • Describes consultation, supplies, overnight shipping and messaging within the offer

Things to consider

  • $399 catalog value does not establish a monthly bill or supply duration
  • Official refund pages conflict: $50 versus $40 consultation plus $70 live-visit fee when applicable

Lyfe Rx's current product page identifies a compounded GIP/GLP-1 containing tirzepatide. Its embedded product and variant data list $399, but that catalog amount does not establish a selected supply duration or recurring total. The page says membership and a multi-month agreement are not required and subscription is optional. Confirm the purchase type and itemized prescription before authorizing payment.3

The catalog price is not the whole contract

The product describes medication, provider consultation, injection supplies, overnight shipping and follow-up messaging as included. Embedded purchase-plan data also contain a discounted subscription amount; no selected discount eligibility, billing interval or usable supply was verified. Compare the actual total and next charge, not an assumed $399 monthly subscription.3

General terms describe automatic renewal for subscription purchases until cancellation through the account's Subscriptions section and allow taxes or shipping where applicable. An intake is required after checkout, and a provider must approve treatment before fulfillment. A product-page no-membership message does not eliminate recurring charges if a subscription is selected.4

TopicWhat to know
Named productCompounded GIP/GLP-1 containing tirzepatide
Catalog data$399 product amount; selected duration unverified
Purchase choiceSubscription optional; confirm actual next charge
InclusionsMedication, consultation, supplies, shipping and messaging described
Catalog and embedded discount data are not a selected prescription quote.3,4

Refund fees conflict across official pages

The dedicated cancellation page permits a refund before a prescription is filled, less a $50 medical-intake and doctor fee. The separate store refund policy instead lists a $40 standard consultation fee plus a $70 live-visit fee if applicable, with no guarantee of cancellation once the prescription reaches the pharmacy. Both make filled or shipped medication generally final. Do not assume one fee schedule supersedes the other without written confirmation.5,6

The product page says nonapproval results in a refund less an administrative fee but does not give that amount. The store policy also contains broad language making service fees and prepaid plans nonrefundable. Ask which agreement governs the selected order, the retained amount if not approved, and the exact filling cutoff. Canceling a future subscription and refunding the current prescription are separate requests.3,5,6

The store policy asks for 48 hours' notice for appointment changes; that is not a verified subscription-renewal deadline. It discusses defective-product review but does not support an unconditional cash refund or replacement promise for every shipping issue. Retain the written response and contact support promptly if a delivery is wrong or damaged.6

TopicWhat to know
Dedicated policyBefore filling, less $50 fee
Store policy$40 consultation plus $70 live visit if applicable; conditions differ
Filled or shippedGenerally final; confirm exact cancellation stage
FDA historySeptember 9, 2025 misleading-marketing letter; current resolution unverified
Resolve the fee conflict in writing; a historical letter is not a current closure finding.5,6,7

What the FDA letter actually says

FDA issued Lyfe Rx a warning letter dated September 9, 2025, after reviewing its website in August 2025. The letter concerns false or misleading efficacy claims for compounded semaglutide and tirzepatide, including implications that the products were the same as FDA-approved drugs. This is a specific historical marketing/misbranding action. It does not establish the company's current response, that every current product violates the law, or a current closure or safety determination.7

The current product page acknowledges that compounded medication is not FDA-approved or equivalent to a branded product. That wording is relevant but does not by itself prove FDA accepted a response or closed the matter. The original brand-drug trial references likewise do not validate a particular compounded batch or Lyfe Rx patient results.1,2,3,7

Confirm accountable care before payment

The retrieved pages describe provider review and independent U.S. pharmacy fulfillment, but do not establish the legal practice or specific pharmacy facility assigned to this order. Obtain those names, your state eligibility, formulation, quantity and follow-up arrangement. A displayed certification claim or generic pharmacy assurance is not independent current credential verification. Weigh the historical regulatory issue and unresolved fee conflict alongside the complete prescription quote.

Further reading

Compounded Tirzepatide Legal Status, Zepbound Side Effects, Tirzepatide Gallbladder, Tirzepatide Thyroid Cancer Warning, Tirzepatide Evidence Guide, Luvo Health Review, Coreage Rx Review, Best/Tirzepatide.

Frequently asked questions

Is Lyfe Rx tirzepatide $399 monthly?

Current embedded product data list $399, but a selected supply duration or recurring total was not verified. The page says subscription is optional; confirm the actual dose, quantity and purchase plan.

What is retained if I cancel before filling?

The dedicated policy says $50, while the store policy lists $40 consultation plus a $70 live-visit fee if applicable. Obtain the governing fee schedule and exact filling cutoff before payment.

What did FDA warn Lyfe Rx about?

The September 9, 2025 letter concerns false or misleading claims for compounded semaglutide and tirzepatide. It is historical regulatory context; current resolution or closure was not established.

References(7)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. Read source
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. Read source
  3. Lyfe Rx (2026). Compounded GIP/GLP-1 product and embedded variant data. Lyfe Rx.
  4. Lyfe Rx (2026). Terms and conditions. Lyfe Rx.
  5. Lyfe Rx (2026). Dedicated cancellation and refund policy. Lyfe Rx.
  6. Lyfe Rx (2026). Store refund policy. Lyfe Rx.
  7. U.S. Food and Drug Administration (2025). Lyfe Rx warning letter, September 9, 2025. FDA. Read source

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.